Akebia Therapeutics (FRA:AX9) 6-Month Price Index: 0.78 (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AX9 Akebia Therapeutics Inc FRA:AX9
51 GF Score
Price €0.77
GF Value €1.04
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Akebia Therapeutics 6-Month Price Index?

Akebia Therapeutics FRA:AX9 +3.90% 51 6-Month Price Index is 0.78 as of Aug. 23, 2026. GuruFocus rates FRA:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.04 (Modestly Undervalued). The stock has 4 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-23), Akebia Therapeutics's 6-Month Price Index is 0.78.

Akebia Therapeutics  (FRA:AX9) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Akebia Therapeutics 6-Month Price Index Related Terms

FRA:AX9 vs ORGO, EBS, TKNO: 6-Month Price Index Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FRA:AX9
51GF Score
Akebia Therapeutics Inc FRA:AX9
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics  (FRA:AX9) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.78 mean?
Akebia Therapeutics (FRA:AX9) has a 6-Month Price Index of 0.78 as of Aug. 23, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' 6-Month Price Index too high?
Akebia Therapeutics' current 6-Month Price Index is 0.78. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' 6-Month Price Index compare to ORGO and EBS?
Akebia Therapeutics' 6-Month Price Index of 0.78 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current 6-Month Price Index is 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (FRA:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.04, compared to a current price of €0.77 — trading 26.2% below its estimated fair value. The current 6-Month Price Index is 0.78. Akebia Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Akebia Therapeutics (FRA:AX9), the current 6-Month Price Index is 0.78 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (FRA:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued. The current stock price of €0.77 is trading 26.2% below its estimated GF Value™ of €1.04. GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.

Key valuation signals for FRA:AX9:

  • 6-Month Price Index: 0.78
  • GF Value™: €1.04 vs. price of €0.77 (26.2% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the FRA:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akebia Therapeutics Business Description

Other Exchanges AKBA:USAAX9:Germany
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score

Get the complete analysis for FRA:AX9

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price
€1.04
GF Value